<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">159</article-id><article-id pub-id-type="doi">10.15690/vramn.v68i8.723</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>PHTHISIOLOGY: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ФТИЗИАТРИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">ROLE OF HEPATOPROTECTORS AND IMMUNOMODULATORS IN REGULATION OF HEPATOCYTE APOPTOSIS INDUCED BY ANTITUBERCULOSIS TREATMENT</article-title><trans-title-group xml:lang="ru"><trans-title>УЧАСТИЕ НЕКОТОРЫХ ГЕПАТОПРОТЕКТОРОВ И ИММУНОМОДУЛЯТОРОВ В РЕГУЛЯЦИИ АПОПТОЗА ГЕПАТОЦИТОВ, ИНДУЦИРОВАННОГО ПРОТИВОТУБЕРКУЛЕЗНЫМИ ПРЕПАРАТАМИ ОСНОВНОГО РЯДА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sukhanov</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Суханов</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, associate professor of the Department of Phthisiopulmonology and Thoracic Surgery, I.I. Mechnikov North-Western State Medical University. Address: St. Petersburg, Kirochnaya Street, 41; tel.: (812) 303-50-00</p></bio><email>dmitriysukhanovl@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bazhanova</surname><given-names>E. D.</given-names></name><name xml:lang="ru"><surname>Бажанова</surname><given-names>Е. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, leading research scientist of the Laboratory of Comparative Somnology and Neuroendocrinology, I. M. Sechenov Institute of Evolutionary Physiology and Biochemistry of RAS. Address: 194223, St. Petersburg, Thorez avenue, 44; tel.: (812) 552-32-27</p></bio><email>bazhanovae@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Teplyi</surname><given-names>D. L.</given-names></name><name xml:lang="ru"><surname>Теплый</surname><given-names>Д. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, professor, member of RANS, Head of the Department of Animal and Human Morphology and Physiology of Astrakhan State University. Address: 414040, Astrakhan, Tatishchev Street, 20a; tel.: (8512) 22-93-47</p></bio><email>dima.tepliy@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, Russian Federation</institution></aff><aff><institution xml:lang="ru">Северо-Западный медицинский университет им. И.И. Мечникова, Санкт-Петербург, Российская Федерация</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Mechnikov Northwest Medical University, St. Petersburg, Russian Federation</institution></aff><aff><institution xml:lang="ru">Институт эволюционной физиологии и биохимии им. И.М. Сеченова РАН, Санкт-Петербург, Российская Федерация</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Аstrakhan State University, Russian Federation</institution></aff><aff><institution xml:lang="ru">Астраханский государственный университет, Российская Федерация</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-08-19" publication-format="electronic"><day>19</day><month>08</month><year>2013</year></pub-date><volume>68</volume><issue>8</issue><issue-title xml:lang="en">Vestnik Rossiiskoi akademii medetsinskikh nauk / Annals of the Russian academy of medical sciences</issue-title><issue-title xml:lang="ru">Вестник Российской академии медицинских наук</issue-title><fpage>45</fpage><lpage>50</lpage><history><date date-type="received" iso-8601-date="2015-08-07"><day>07</day><month>08</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 1970, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 1970, Издательство "Педиатръ"</copyright-statement><copyright-year>1970</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/159">https://vestnikramn.spr-journal.ru/jour/article/view/159</self-uri><abstract xml:lang="en"><p><italic>It was currently shown that hepatopathy due to drug toxicity is associated with increased apoptosis of hepatocytes. Therefore, development of drugs which regulate cell death is of great importance. </italic><bold><italic>A</italic><italic>im</italic></bold><italic>: to involve some hepatoprotectors (ademethionine, reamberin, remaxol) and immunomodulators (cycloferon) into regulation of apoptosis in experimental models of liver first-line antituberculousis drugs (isoniazid, rifampicin, pyrazinamide). </italic><bold><italic>Materials and methods</italic></bold><italic><bold>:</bold> levels of apoptosis (TUNEL), expression of CD95 (receptor of tumor necrosis factor ― </italic><italic>by</italic><italic> </italic><italic>immunohistochemistry), expression of caspase-8, caspase-3 and p53 (Western-blotting) were measured. </italic><bold><italic>Results</italic></bold><italic>: exposition </italic><italic>of</italic><italic> </italic><italic>first-line antituberculousis drugs leads to dysthrophia of liver parenchyma cells with increased apoptosis of hepatocytes and activation of CD95, caspase-8 (external way) and overexpression of p53 and caspase-3. It was found that reamberin, cycloferon and remaxol have hepatoprotective effect improving liver histology; ademethionine administered by intraperitoneal injection showed no positive effects. Reamberin demonstrated apoptosis-inhibiting effect in the experiment whereas other drugs were found to be apoptosis inductors for hepatocytes in toxic hepatopathy. </italic><bold><italic>Conclusions</italic></bold><italic><bold>:</bold> </italic><italic>r</italic><italic>egulation of apoptosis by cycloferon and remaxol mediated by external and p53-dependent pathway is confirmed by increased expression of CD95 and p53 protein. Ademethionine might induce apoptosis by the intrinsic pathway.</italic></p><p> </p></abstract><trans-abstract xml:lang="ru"><p><italic>В настоящее время показано, что гепатопатия вследствие лекарственной интоксикации связана с повышением уровня апоптоза гепатоцитов. Следовательно, большое значение получают препараты, регулирующие клеточную гибель. </italic><bold><italic>Цель</italic></bold><italic><bold>: </bold>изучить участие в регуляции апоптоза некоторых гепатопротекторов (</italic><italic>адеметионин</italic><italic>, реамберин, ремаксол) и иммуномодуляторов (циклоферон) на модели экспериментального поражения печени противотуберкулезными препаратами первого ряда (изониазид, рифампицин, пиразинамид). </italic><bold><italic>Материалы и методы</italic></bold><italic>: определяли уровень апоптоза (</italic><italic>TUNEL</italic><italic>), </italic><italic>экспрессию </italic><italic>CD95 (рецептор</italic><italic>a</italic><italic> фактора некроза опухоли</italic><italic> — иммуногистохимически),</italic><italic> экспрессию каспазы-8, -3, а также </italic><italic>p</italic><italic>53 (вестерн-блоттингом). </italic><bold><italic>Результаты</italic></bold><italic>: установлено, что введение противотуберкулезных препаратов первого ряда приводит к дистрофии клеток паренхимы печени с повышением уровня апоптоза гепатоцитов с активацией </italic><italic>CD</italic><italic>95, каспазы-8 (внешнерецепторный путь) и оверэкспрессией р53 и каспазы-3. Реамберин, циклоферон и ремаксол продемонстрировали гепатопротективное действие, улучшая гистологическую картину печени; а</italic><italic>деметионин</italic><italic> при внутрибрюшинном введении не показал положительных эффектов. Реамберин продемонстрировал апоптоз-ингибирующее действие в эксперименте, однако остальные препараты проявили себя как индукторы апоптоза гепатоцитов в условиях токсической гепатопатии. </italic><bold><italic>Выводы</italic></bold><italic>: регуляция апоптоза циклофероном и ремаксолом осуществляется по внешнерецепторному и р53-зависимому пути, о чем свидетельствует увеличение экспрессии белков </italic><italic>CD</italic><italic>95 и р53. А</italic><italic>деметионин, вероятно,</italic><italic> индуцирует апоптоз посредством внутреннего пути.</italic></p><p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>hepatoprotectors</kwd><kwd>cycloferon</kwd><kwd>apoptosis prevention</kwd><kwd>tuberculosis</kwd><kwd>liver damage</kwd><kwd>reamberin</kwd><kwd>remaxol</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гепатопротекторы</kwd><kwd>циклоферон</kwd><kwd>апоптозпротективная активность</kwd><kwd>туберкулез</kwd><kwd>поражения печени</kwd><kwd>реамберин</kwd><kwd>ремаксол</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Balasubramanian A., Munshi N., Koziel M.J. Hu Z., Liang T.J., Groopman J.E., Ganju R.K. Structural proteins of hepatitis С virus induce interleukin 8 production and apoptosis in human endothelial cells. J. Gen. Virol. 2005; 86: 3291–3301.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Kuo C.Y., Chou T.Y., Chen C.M., Tsai Y.F., Hwang G.Y., Hwang T.L. Hepatitis B virus X protein disrupts stress fiber formation and triggers apoptosis. Virus Res. 2013; 175 (1): 20–29.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Morio Y., Tsuji M., Inagaki M., Nakagawa M., Asaka Y., Oyamada H., Furuya K., Oguchi K. Ethanol-induced apoptosis in human liver adenocarcinoma cells (SK-Hep1): Fas- and mitochondria-mediated pathways and interaction with MAPK signaling system. Toxicol. In Vitro. 2013; 27 (6): 1820–1829.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Miao H.L., Pan Z.J., Lei C.J., Wen J.Y., Li M.Y., Liu Z.K., Qiu Z.D., Lin M.Z., Chen N.P., Chen M. Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP. J. Cell Biochem. 2013; 114 (3): 625–631.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Ghavami S., Hashemi M., Kadkhoda K., Alavian S.M., Bay G.H., Los M. Apoptosis in liver diseases — detection and therapeutic applications. Med. Sci. Monit. 2005; 11 (11): 3337–3345.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	An J., Mehrhof F., Harms C., Lättig-Tünnemann G., Lee S.L., Endres M., Li M., Sellge G., Mandić A.D., Trautwein C., Donath S. ARC is a novel therapeutic approach against acetaminophen-induced hepatocellular necrosis. J. Hepatol. 2013; 58 (2) : 297-305.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	Bol'f S.B., Sukhanov D.S., Romantsov M.G. Drug-induced liver damage in chemotherapy of tuberculosis. Vestn. S.Pb. Gos. med. akad. I.I. Mechnikova - Bulletin of the St. Petersburg Medical Academy of Postgraduate Education named after I. Mechnikov. 2009; 1: 172–176.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Slivka Yu.I. Comparative characteristics of hepatotoxicity of isoniazid, rifampicin and pyrazinamide. Farmakol. i toksikol. = Pharmacology and Toxicology. 1989; 4: 82–85.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Zeits G. Alcoholic liver disease. Ross. zhurn. gastroent. gepatol. Koloproktol = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2001; 4: 62–65.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	García-Vaquero M., Benedito J.L., López-Alonso M., Miranda M. Histochemistry evaluation of the oxidative stress and the antioxidant status in Cu-supplemented cattle. Animal. 2012; 6 (9): 1435–1443.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	Lu Y., Chen G.Q. Effector caspases and leukemia. Int. J. Cell Biol. 2011; 738301. doi: 10.1155/2011/738301.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.	Bazhanova E.D. Cycloferon: mechanism of action, functions and application. Zhurn. eksperim. i klinich. farmakol = Journal of Experimental and Clinical Pharmacology. 2012; 75 (7): 40–44.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.	Shevyreva E.V., Ivanov A.K., Sukhanov D.S., Murzina A.A. Remaxol hepatoprotective therapy in patients with tuberculosis and HIV infection in day hospital of tuberculosis dispensary. Antibiotiki i khimioterapiya - Antibiotics and Chemotherapy. 2012; 7 (8): 31–37.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.	Lee E.S., Chen H., Hardman C., Simm A., Charlton C. Excessive S-adenosyl-L-methionine-dependent methylation increases levels of methanol, formaldehyde and formic acid in rat brain striatal homogenates: possible role in S-adenosyl-L-methionine-induced Parkinson's disease-like disorders. Life Sci. 2008; 83 (25–26): 821–827.</mixed-citation></ref></ref-list></back></article>
